Recently, several reports have linked resistance to serine/threonine protein kinase BRAF (BRAF) inhibitors with augmented glutamine dependency [37,38,39], suggesting that altered glutamate-dependent anabolic pathways may be central to acquiring drug resistance in cancers including melanoma. Here, BRAF is linked to melanoma.